Morphic only had eyes for Eli Lilly. While some takeover tales have casts of Shakespearean breadth, Lilly’s $3.2 billion Morphic buyout is a simpler story of two companies gradually closing the gap ...
Morphic Ethical Equities Fund Ltd. ( ($AU:MEC) ) has issued an update. Morphic Ethical Equities Fund Limited has updated the market on its ongoing ...
WALTHAM, Mass.–(BUSINESS WIRE)–Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the closing of its ...
Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced Monday, a transaction that includes an experimental medication for inflammatory ...
Eli Lilly has agreed to buy Morphic for $3.2 billion, giving the Big Pharma control of an oral, midphase challenger to Takeda’s injectable inflammatory bowel disease blockbuster Entyvio. Morphic’s ...
Morphic Ethical Equities Fund Ltd. ( ($AU:MEC) ) has issued an update. Morphic Ethical Equities Fund Limited has released its estimated unaudited ...
WALTHAM, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ...
A series of positive news is helping the biopharmaceutical company start the week on a strong note. Morphic Holding reported interim data from a phase 1 clinical trial for MORF-057, a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback